MMV Request for Proposals: 19th Call for Drug Discovery
Medicine for Malaria Venture (MMV) with the mission to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs. MMV welcomes proposals in the following areas of the drug discovery process:
1. Drug discovery projects:
- Compounds having activity against Plasmodium falciparum blood stages and ideally an inability to select resistant mutants in vitro (TCP1): novel chemical series with EC50<500nM.
- Compounds having activity against Plasmodium falciparum liver stages for use in prophylaxis (TCP4): novel chemical series with EC50<500nM.
- Compounds addressing the key priorities of the malaria eradication agenda (TCP3 and TCP5): novel families of molecules in the hit-to-lead or lead optimization stages, without G6PD deficiency liabilities.
2. Compounds for target identification: MMV also welcomes requests for support to investigate the mechanism of action of compounds:
- Plasmodium whole cell EC50 <1uM and the chemical structure can be shared
- At least 10mgs of compound can be provided to the consortium
3. African proposals: finally, MMV welcomes proposals only from endemic region African scientists focused in the following priority areas:
- Compounds with confirmed activity on any antimalarial life-cycle stage
- Assay development and screening
Read more here.
Proposals deadline March 26, 2021.
